Welcome to the Duke Human Vaccine Institute
The Duke Human Vaccine Institute (DHVI) continues to lead with cutting edge vaccine research against infectious diseases that impact global health.
Scientists at the DHVI conduct basic and translational research to develop novel vaccines, therapeutics, and diagnostics for diseases such as HIV-1, influenza, SARS-CoV-2, tuberculosis, syphilis, and gonorrhea. Several DHVI basic science discoveries are currently being produced in Good Manufacturing Practice (CGMP) facilities for early phase vaccine trials.
DHVI has established a place of national and international leadership in the fight against major infectious diseases. We play an integral leadership role in the Global HIV/AIDS Vaccine Enterprise and we are a pioneer in emerging infections and biodefense research.
Why has an HIV vaccine been so difficult to develop over the past 35 years? Learn about the challenges and major milestones from a phase 1 clinical trial.
Join us in leading the fight against major infectious diseases!
Listen directly from our scientists as they explain the path to creating a universal vaccine to fight future coronaviruses.